Menumenu

News

  • News

    Anticoagulant treatment after VTE in the Netherlands: A retrospective cohort study

    Treatment after venous thromboembolism (VTE) as captured in observational healthcare data generally follows the Dutch guidelines, except for the duration of low-molecular-weight heparin treatment, which was longer than recommended. This was concluded...

  • News

    The effect of switching from Thyrax Duotab to other brands of levothyroxine
    First results and interim advice

    First results and interim advice The stock-out of Thyrax Duotab in the Netherlands forced thousands of Thyrax Duotab users to switch to other brands of levothyroxine. The Dutch Society for Endocrinology (NVE) and the Dutch Thyroid Organisation (S...

  • News

    PHARMO study published in Current Medical Research and Opinion

    Characterisation and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands. Over 40% of monitored patients in the Netherlands with established cardiovascular disease or type 2 diabetes mellitus and L...

  • News

    PHARMO study published in BMC Urology

    Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride The risk of undergoing BPH-related prostate surgery was lower among men using dutasteride compared to men using fin...

  • News

    Find our latest newsletter online

    In the current issue: Tailored algorithm for the Chronic Disease Score, PHARMO at the PhUSE Conference PHARMO's latest newsletter is published online, click here to read it. Subscribe to our newsletter to receive every new edition in your mail...

  • News

    PHARMO scientific annual report 2016 available
    The PHARMO scientific annual report was created to inform our healthcare providers and partners on the research that is done with their data

    The PHARMO scientific annual report was created to inform our healthcare providers and partners on the research that is done with their data. Without these data the PHARMO Institute would not be able to perform research. In the report the current ...

  • News

    The PHARMO Institute and X-IS have joined forces:
    PHARMO and X-IS created a proof of concept that provides insight into the use and outcomes of expensive medicines in hospitals!

    PHARMO and X-IS created a proof of concept that provides insight into the use and outcomes of expensive medicines in hospitals! By linking data from DICA registrations, pharmaceuticals and financial information we provide hospital management, medi...

  • News

    PHARMO presentation “Expensive medicines linked to quality registry: insight into costs and appropriate use”

    Our Manager Research Department, Myrthe van Herk-Sukel presented together with Jan van der Eijk, (advisor X-IS) at the DICA convention on the 16th of June, the first results of the Rx-pilot from DICA, the PHARMO Institute and X-IS. During the Rx-...

  • News

    Study on the effect of switching from Thyrax Duotab to other brands of levothyroxine
    In collaboration with the Dutch Society for Endocrinology (NVE), the Dutch Thyroid Organisation (SON) and the Netherlands Institute for Health Services Research (NIVEL)

    The Dutch Ministry of Health, Welfare and Sport (VWS) requested the Netherlands Organisation for Health Research and Development (ZonMw) to finance a study on the effect of switching from Thyrax Duotab to other brands of levothyroxine after a stock-o...

  • News

    Webinar on sequential treatment analysis
    by Edith Heintjes, Scientific Research Manager at the PHARMO Institute

    On March 23rd, 2016 Edith Heintjes, PhD, gave a webinar on sequential treatment analysis. The presentation on “Challenges of sequential treatment analysis” focused on the methodological challenges of patient centric treatment pattern analysis....